Please ensure Javascript is enabled for purposes of website accessibility

Why Heron Therapeutics Stock Jumped Today

By Keith Speights - May 10, 2021 at 3:33PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors liked the company's Q1 update.

What happened

Shares of Heron Therapeutics (HRTX 10.87%) were jumping 7.3% as of 3:08 p.m. EDT on Monday after rising as much as 13% earlier in the day. The gain came after the drugmaker provided its first-quarter update Monday morning.

So what

Heron announced Q1 revenue of $20 million, down 21% year over year. It reported a net loss of $52.6 million, or $0.58 per share. The average analysts' estimate projected Q1 revenue of $25.7 million and a loss of $0.57 per share.

Test tubes on rack with increasingly higher levels of green liquid from left to right and a green line with an arrow in the background sloping upward

Image source: Getty Images.

Why did the biotech stock move higher with Heron missing both top- and bottom-line estimates? The company thinks that the worst is over for Cinvanti, which is used to treat chemotherapy-induced nausea and vomiting. Heron signed a big multiyear contract for the drug that should enable it to grow market share throughout the rest of this year and beyond.

Now what

The U.S. Food and Drug Administration (FDA) is scheduled to announce its approval decision for HTX-011 in managing post-operative pain on May 12. Heron CEO Barry Quart said that the company is preparing for a commercial launch of the drug in the U.S.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Heron Therapeutics, Inc. Stock Quote
Heron Therapeutics, Inc.
HRTX
$3.57 (10.87%) $0.35

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.